James Schaub's most recent trade in RVL Pharmaceuticals plc was a trade of 5,577 Ordinary Shares done at an average price of $0.9 . Disclosure was reported to the exchange on May 18, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 18 May 2023 | 5,577 | 524,835 (0%) | 0% | 0.9 | 4,852 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 24 Jan 2023 | 9,608 | 530,412 (0%) | 0% | 1.3 | 12,106 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Purchase of securities on an exchange or from another person at price $ 1.55 per share. | 08 Aug 2022 | 150,000 | 540,020 (0%) | 0% | 1.6 | 232,500 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.40 per share. | 18 May 2022 | 6,273 | 390,020 (0%) | 0% | 1.4 | 8,782 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Jan 2022 | 9,607 | 396,293 (0%) | 0% | 1.1 | 10,856 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Purchase of securities on an exchange or from another person at price $ 1.07 per share. | 16 Dec 2021 | 93,800 | 405,900 (0%) | 0% | 1.1 | 100,366 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2021 | 249,814 | 249,814 | - | - | Share Option (Right to Buy) | |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 18 May 2021 | 6,621 | 312,100 (0%) | 0% | 3.1 | 20,658 | Ordinary Shares |
| RVL Pharmaceuticals plc | James Schaub | EVP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.46 per share. | 24 Jan 2021 | 9,687 | 318,721 (0%) | 0% | 4.5 | 43,204 | Ordinary Shares |